Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 15.4% during trading on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. Approximately 382,000 shares changed hands during trading, a decline of 37% from the average daily volume of 601,939 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The company has a market capitalization of C$27.01 million, a price-to-earnings ratio of -15.50 and a beta of 0.20. The business has a 50-day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- 3 Warren Buffett Stocks to Buy Now
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What is a Low P/E Ratio and What Does it Tell Investors?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What is Insider Trading? What You Can Learn from Insider Trading
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
